Sanofi

Q2 2025 13F Holdings

  • Location
    paris, I0
  • Num holdings

    10

  • Value ($000)

    $175,743

  • Date Filed
    07/29/2025
  • Form type
    13F-HR
  • CIK
    0001121404
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q2 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

MeiraGTx Holdings plc

COM
G59665102
$79.53 M
45 %

12,197,737

NVV1
NVV1

Novavax

COM NEW
670002401
$43.35 M
25 %

6,880,481

ANAB
ANAB

AnaptysBio

COM
032724106
$18.25 M
10 %

821,917

INBX
INBX

Inhibrx Biosciences, Inc.

COM
45720N103
$16.52 M
9 %

1,157,926

---

Omada Health Inc.

COM
68170A108
$9.61 M
6 %

524,903

---

LAVA Therapeutics N.V.

SHS
N51517105
$2.53 M
1 %

1,919,455

ELDN
ELDN

Eledon

COM
28617K101
$2.21 M
1 %

814,980

INZY
INZY

Inozyme, Inc

COM
45790W108
$1.77 M
1 %

443,255

IGMS
IGMS

IGM Biosciences

COM
449585108
$1.61 M
1 %

1,438,975

QTTB
QTTB

Q32 Bio Inc.

COM
746964105
$363.68 K
0 %

244,083

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 10